Alvotech and advanz pharma extend strategic partnership to commercialize three additional biosimilars in europe

Reykjavik, iceland and london, may 28, 2025 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and advanz pharma, a uk headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in europe, today announced that the companies have entered into an agreement to expand their commercial partnership to cover three additional biosimilar candidates.
ALVO Ratings Summary
ALVO Quant Ranking